Effect of cell proliferation pathway on accessibility to targeted therapeutics in the spectrum of co-occurring prognostic cellular pathways in pan-cancers.

e15092 Background: Cellular pathways play a crucial role in prognosis and development of targeted therapies by impacting molecular mechanisms underlying disease progression. Targeted therapies can significantly reduce side effects while offering the potential to overcome challenges like drug resistance. This study aims to investigate prognostic cellular pathways that may be promising in guiding drug interactions pan-cancers. Methods: A cohort of 82 pan-cancer patients (Breast, Colorectal, Endometrium, Gall Bladder, Gastric, HNC, Lung, Melanoma, Ovary, Pancreas, Prostate, Urothelium) were retrospectively analyzed to understand the distribution of cellular pathways. Next Generation Sequencing (NGS) test was performed using OncoIndx Assay. Results: A total of 99 genomic alterations distributed across cellular pathways including proliferation, progression, dsDNA Repair, mismatch repair (MMR), tumor suppression and cell signaling were detected. Cell proliferation pathway alterations constituted the highest frequency with 43 mutations in 34.14% of patients while 31 alterations in tumor suppressor genes were identified in 34.14% patients. MMR and cell signaling pathways included a minor 2 and 1 alterations. Crucial pathways were also identified to co-occur with cell proliferation including tumor suppression (n = 13/28), cell progression (n = 2/28), dsDNA repair (n = 3/28), and MMR pathways (n = 2/28). From this group, 1 patient had recently undergone surgery showing no e/o recurrence or residual disease and the other patient was started with oral chemotherapy (capecitabine). Interestingly, both patients showed co-occurring tumor suppression pathway alterations. Conclusions: Cell proliferation pathway alterations, by presenting themselves as co-occurring with tumor suppression, cell progression, dsDNA repair and MMR pathway, open newer targets for multiple treatment lines.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-05-28
DOI
https://doi.org/10.1200/jco.2025.43.16_suppl.e15092
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of cell proliferation pathway on accessibility to targeted therapeutics in the spectrum of co-occurring prognostic cellular pathways in pan-cancers.

Mohan Uttarwar, Mina Darooei, Sourav Mishra, Atul Bharde et al.
Journal of Clinical Oncology
Lung Cancer Treatments and Mutations
article

Effect of cell proliferation pathway on accessibility to targeted therapeutics in the spectrum of co-occurring prognostic cellular pathways in pan-cancers.

Mohan Uttarwar, Mina Darooei, Sourav Mishra, Atul Bharde, Aravindan Vasudevan, Jayant Khandare, Sandhya Iyer, Aarthi Ramesh, Nidhi Patel, Gowhar Shafi
article en

Abstract

e15092 Background: Cellular pathways play a crucial role in prognosis and development of targeted therapies by impacting molecular mechanisms underlying disease progression. Targeted therapies can significantly reduce side effects while offering the potential to overcome challenges like drug resistance. This study aims to investigate prognostic cellular pathways that may be promising in guiding drug interactions pan-cancers. Methods: A cohort of 82 pan-cancer patients (Breast, Colorectal, Endometrium, Gall Bladder, Gastric, HNC, Lung, Melanoma, Ovary, Pancreas, Prostate, Urothelium) were retrospectively analyzed to understand the distribution of cellular pathways. Next Generation Sequencing (NGS) test was performed using OncoIndx Assay. Results: A total of 99 genomic alterations distributed across cellular pathways including proliferation, progression, dsDNA Repair, mismatch repair (MMR), tumor suppression and cell signaling were detected. Cell proliferation pathway alterations constituted the highest frequency with 43 mutations in 34.14% of patients while 31 alterations in tumor suppressor genes were identified in 34.14% patients. MMR and cell signaling pathways included a minor 2 and 1 alterations. Crucial pathways were also identified to co-occur with cell proliferation including tumor suppression (n = 13/28), cell progression (n = 2/28), dsDNA repair (n = 3/28), and MMR pathways (n = 2/28). From this group, 1 patient had recently undergone surgery showing no e/o recurrence or residual disease and the other patient was started with oral chemotherapy (capecitabine). Interestingly, both patients showed co-occurring tumor suppression pathway alterations. Conclusions: Cell proliferation pathway alterations, by presenting themselves as co-occurring with tumor suppression, cell progression, dsDNA repair and MMR pathway, open newer targets for multiple treatment lines.

Journal of Clinical OncologyVol. 43(16_suppl)
All India Institute of Medical Sciences Bhubaneswar (IN)
Openalex Percentile: Top 80%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.